撰文丨王聪 编辑丨王多鱼 排版丨水成文 随着年龄的增长，肝脏更容易出现 代谢功能障碍相关脂肪性肝炎 （MASH） 纤维化。破解衰老、肝脏中衰老细胞的出现与 MASH 纤维化之间复杂的相互作用， 对于开发治疗方法至关重要。 2025 年 5 月 19 日， 中国科学院脑科学与智能技术卓越创新中心 蔡时青 团队与 复旦大学公共卫生中心 涂传涛 团队合作，在 Nature 子刊 Nature Aging 上发 表了题为： Targeting the chromatin remodeler BAZ2B mitigates hepatic senescence and MASH fibrosis 的研究论文。 该研究首次揭示，表观遗传调控因子 BAZ2B 在 肝脏衰老 及 代谢功能障碍相关性脂肪肝炎 （MASH） 纤维化中的关键作用，为开发新型治疗策略奠定理论基 础。 在这项新研究中，研究团队揭示了一种表观遗传机制，该机制将肝脏衰老与 MASH 纤维化联系起来。 研究团队发现，在部分肝细胞中染色质重塑因子 BAZ2B 的上调与患者的 MASH 病理有关。 在小鼠模型中，通过基因敲除或肝细胞特异性敲低 Baz2b 可通过 ...

Core Insights - NewLimit, a startup focused on epigenetic reprogramming, raised $130 million in Series B funding led by Kleiner Perkins, with participation from existing investors like Founders Fund and Khosla Ventures, to address global health challenges posed by an aging population [1][15][16] - The company aims to leverage AI-driven epigenetic reprogramming technology to tackle the pressing issue of "healthy aging," as the global population aged 60 and above is projected to increase from 1 billion in 2020 to 2.1 billion by 2050 [1][15] Company Overview - Founded in 2021 by Brian Armstrong, co-founder of Coinbase, and Blake Byers, a former partner at Google Ventures, NewLimit embodies a "tech + bio" hybrid model, integrating venture capital and scientific expertise [2][3] - The company currently employs 34 scientists, engineers, and staff, with over 90% in technical roles, reflecting its commitment to innovation at the intersection of biotechnology and artificial intelligence [2] Scientific Foundation - NewLimit's approach is based on significant scientific discoveries, including the work of Shinya Yamanaka, who demonstrated that activating four key transcription factors can partially restore the youthful state of aging human skin cells [5][6] - The company aims to identify small molecules that can precisely modulate cellular epigenetic states, effectively "resetting" cells to a more youthful functional phenotype [5][6] Technological Advancements - NewLimit's "discovery engine" integrates high-throughput experimental platforms with AI predictive models, significantly enhancing the efficiency of drug target identification by hundreds of times [6] - The company has made substantial progress in transitioning from basic research to preclinical applications, with a focus on liver function restoration and immune rejuvenation [7][9] Clinical Applications - NewLimit's pipeline includes promising applications such as: - Liver function restoration targeting liver cells, with lead compound M003 showing an 85% recovery rate in alcoholic liver disease models [8][9] - Immune rejuvenation through specific transcription factor combinations that restore the functionality of aging CD8+ T cells [8][9] - The company has achieved key breakthroughs, including the establishment of a lipid nanoparticle delivery system for mRNA, facilitating the development of both small and large molecule therapies [9][11] Market Context - The global anti-aging market is projected to reach $348.3 billion by 2032, with a compound annual growth rate of nearly 5%, driven by the increasing population aged 60 and above [15][17] - NewLimit's funding trajectory reflects strong investor confidence in its technological approach and the broader trend of major tech companies entering the longevity economy [15][17] Implications for the Industry - NewLimit's development path offers insights for the Chinese anti-aging industry, emphasizing the importance of platform-based approaches, cross-disciplinary teams, and targeted applications in quantifiable functional restoration [19][20] - With ongoing advancements in AI, big data, and biomanufacturing, China is positioned to carve out a sustainable path in anti-aging technology development, contributing to high-quality growth in the biopharmaceutical sector [19][20]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 2012 年， CRISPR-Cas9 的发现开启了基因编辑新时代，此后的十多年里， 基于 CRISPR 的基因编辑技术 得到了快速发展，并被成功应用放到了人体临床试验中已治疗遗传疾病和癌症。与此同时，全世界的科学 家们也在不断挖掘新的具有基因编辑潜力的新工具，以解决 Cas9 蛋白体积过大 （约1400个氨基酸） ，难 以通过 AAV 病毒载体进行递送以进行体内基因编辑的难题。 该研究通过对 CRISPR-Cas9 的祖先 IscB 进行进化改造， 成功创造出仅有 Cas9 一半大小的 NovalscB 系统 （仅 614 个氨基酸） ，基因编辑效率提升百倍，研究团队将 NovalscB 系统与 甲基转移酶融合，进而创建 一个可编程的表观遗传编辑系统—— OMEGAoff ，其 紧凑程度足以被装载到单个 腺相关病毒 （AAV） 载 体中，通过单次 AAV 注射即可实现长达 6 个月的持久基因表达抑制。 2025 年 5 月 7 日， 张锋 团队在 Nature Biotechnology 期刊发表了题为： Evolution-guided protein design ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 " 科学和医学领域已研发出了非凡的疗法以减轻疾病负担，然而针对衰老相关病理的治疗手段却始终难以获 取。我们坚信，表观遗传重编程能够为这类疾病开启全新的治疗途径。 "—— NewLimit 2025 年 5 月 6 日，抗衰老生物科技公司 NewLimit 宣布完成 1.3 亿美元 B 轮融资， 此轮融资由凯鹏华盈 （Kleiner Perkins） 领投，新投资者 Nat Friedman/Daniel Gross、Khosla Ventures 和 Human Capital 跟投。 NewLimit 成立于 2022 年，由谷歌风投 （GV） 合伙人 Blake Byers 博士、加密货币交易平台 Coinbase （纳 斯达克上市公司，目前市值约 500 亿美元） 联合创始人兼 CEO Brian Armstrong 以及表观遗传重编程专家 Jacob Kimmel 博士共同创立。该公司此前已完成 1.5 亿美元融资，此次 B 轮融资后，公司估值提升至 8.1 亿美元。 NewLimit 的目标是 研发能够 重编程衰老细胞 以 延长健康寿命 的药物 ， 通过重编程 ...

2015 年，韩国仁荷大学的研究人员在对公元 1392-1910 年之间的朝鲜皇家各成员血统纪录进行仔细分析 后发现，一个世纪前，太监 （被阉割的男性） 也比其他男性活得更久，其平均寿命要比正常男性长 14- 19 年。 不仅如此，阉割延长寿命这一观点在中国的封建王朝历史中也得到体现。据《中国帝王皇后亲王公主世系 录》记载，中国历代帝王平均寿命只有 40 岁，而那些服侍他们的太监，平均寿命却高达 71 岁。 而近期发表的一系列研究成果， 揭示了雄性寿命更短背后的"幕后黑手"—— 雄激素 。 编辑丨王多鱼 排版丨水成文 长寿长生是人类永恒的愿景。有趣的是，在哺乳动物中， 雌性通常比雄性寿命更长，人类也不例外 。据世 界卫生组织和联合国人口组织统计，全球范围内男性平均寿命比女性要短 5-10 年。据统计，2022 年中国 男性平均预期寿命为 76.5 岁，女性则为 82.9 岁，差距同样十分明显。 2023 年 5 月，得克萨斯大学圣安东尼奥健康科学中心长寿与衰老研究所的 James Nelson 教授团队在 Aging Cell 期刊发表了题为： Prepubertal castration eliminate ...

Company Overview - Microchip Biotech is a pioneer in original innovative drugs in China, focusing on providing clinically needed revolutionary mechanism drugs for patients [7][38] - The company has established a complete industrial chain layout from early exploratory discovery to commercialization, offering original innovative drugs globally [38] Financial Performance - For the fiscal year 2024, the company reported a net profit attributable to shareholders of -114.57 million yuan, with the parent company achieving a net profit of -88.42 million yuan [5] - The board decided not to distribute cash dividends or issue bonus shares for the fiscal year 2024, despite having positive undistributed profits [5] Product Pipeline - The company has developed two innovative drugs, with multiple indications approved for sale globally, including in the fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [7][39] - Key products include: - **Sida Benamide (西达本胺)**: A first-in-class HDAC inhibitor with multiple indications approved in China and Japan, including for peripheral T-cell lymphoma and breast cancer [8][9][39] - **Siglitazone (西格列他钠)**: A first-in-class PPAR agonist approved for type 2 diabetes and recently for combination therapy with metformin [12][13][40] Research and Development - The company employs a team of experienced scientists to drive drug development, focusing on understanding disease mechanisms and optimizing drug design [22] - The R&D pipeline includes several promising candidates targeting various cancers and metabolic diseases, with ongoing clinical trials demonstrating significant efficacy [17][21][40] Industry Context - The biopharmaceutical industry in China is rapidly evolving, with increasing participation in global biotech innovation and a focus on meeting domestic healthcare needs [26][30] - Despite a low-risk appetite in global financing, Chinese companies are becoming significant players in licensing transactions, with a notable increase in outbound licensing activities [29][41] - The market for innovative drugs in China is projected to grow significantly, with a forecasted market size of approximately $197 billion by 2025 [30]

VolitionRX Limited (VNRX) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Operator - Conference Call OperatorLouise Batchelor - Group Chief Marketing and Communications OfficerModerator - Conference Call ModeratorCameron Reynolds - Group Chief Executive OfficerTerry Cuse - Group Chief Financial OfficerTerry Cuse - Group Chief Financial OfficerDr. Andrew Retter - Chief Medical Officer Conference Call Participants Stephen Ralston - Analyst at ZaxBruce Jackson - Analyst, Benchm ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wainwright Maury Raycroft - Jefferies Nicole Germino - Truist Gena Wang - Barclays Operator Good afternoon, and welcome ...